LBPO.ET04 · 实验与分子治疗 · Late-Breaking
Late-Breaking Research: Experimental and Molecular Therapeutics 4
-
- LB455 LB455 AT-108的临床前疗效与生物标志物表征：一种首创的原位肿瘤向树突状细胞重编程剂 Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent Fritiof Åkerström, Xavier Catena, Marta Santiago, Ana Perego, Ruixian Liu, Arun Sundaramurthy, Lihan Xie, Emilie Renaud, Andreea-Medeea Matei, Xiaoli Huang, Emma Leire, Ozcan Met, Inge-Marie Svane, Shane Olwill, Cristiana Pires, Filipe Pereira, Fabio Rosa
-
- LB457 LB457 核糖核苷酸还原酶抑制在基因定义的NSCLC中触发铁死亡 Ribonucleotide reductase inhibition triggers ferroptosis in genetically defined NSCLC Triparna Sen
-
- LB459 LB459 BCCA7693——一种新型口服生物利用度DNA-PK抑制剂，通过抑制获得性耐药的发生，与靶向治疗药物联合展现疗效 BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted therapeutics by inhibiting the development of acquired resistance Alastair H. Kyle, Judit P. Banath, Sevin Teymori, Ela Smiljanic-Hurley, Simon Osborne, Jay Paquette, Steve Arns, Claudio Sturino, Joseph Mancini, Andrew I. Minchinton
- LB460 LB460 ARTS-051的表征：一种强效、选择性的Werner解旋酶抑制剂，对多种MSI-H结直肠癌模型有效 Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models Christine Moomau, Jiaqi Liang, Jian Lin, Xiaozhi Yang, Wenheng Liang, John Campbell, Yipin Lu, David Pirovich, Tao Ji, Lina Gu, Fang Li, Yaoyu Chen, Xiang Zhai
- LB461 LB461 PARP1在单链DNA断裂处活性及捕获的原位测量 In situ measurement of PARP1 activity and trapping at single-strand DNA breaks Franek Sierpowski, Katarzyna Fryt, Jakub Lechowski, Zsombor Prucsi, Agnieszka Waligórska, Magdalena Kordon-Kiszala, Kamil Solarczyk
-
- LB464 LB464 PCDC5RP缺陷导致嘧啶相关通路的代谢异常，驱动癌细胞的遗传不稳定性 PCDC5RP deficiency leads to metabolic abnormalities in pyrimidine-associated pathways, driving genetic instability in cancer cells Hyunjin Shin, Mi-Yeun Kim, Jong-kuk PARK
-
-
- LB467 LB467 PF-08634404（一种在研的抗PD-1和抗VEGF双特异性抗体）的剂量优化和暴露-反应（ER）分析 Dose optimization and exposure-response (ER) analysis for PF-08634404, an investigational anti-PD-1 and anti-VEGF bispecific antibody Erik Hahn, Alan Liu, Donald Irby, Nathan Braniff, Mary Campbell, Xiasong Zhang, Manisha Lamba, Donghua Yin, Mohamed Elmeliegy, Jennifer Hibma
- LB468 LB468 ALETA-001的药代动力学，一项CRUK首次人体1/2期试验，针对既往接受过抗CD19 CAR T细胞治疗的B细胞恶性肿瘤患者 Pharmacokinetics of ALETA-001, a CRUK first-in-human phase I/II trial in patients who have received anti-CD19 CAR T-cell therapy for B-cell malignancies Martin Galler, David Jamieson, Paul Rennert, Jenny Craigen, Gareth Veal
- LB469 LB469 EP4拮抗剂HTL0039732的药代动力学——一项针对晚期实体瘤患者的CRUK首次人体I期临床试验 Pharmacokinetics of the EP4 antagonist HTL0039732, a CRUK first-in-human phase I trial in patients with advanced solid tumours Dan Astley, Shelby Barnett, Bristi Basu, Debashis Sarker, Natalie Cook, Stefan N. Symeonides, Svatopluk Svetlik, Derrick Spencer-Briggs, Graeme Scarfe, Nigel Swain, Gareth J. Veal
-
-
-
- LB473 LB473 JNJ-95437446：一种用于实体瘤适应症的基于amivantamab的EGFR/MET-ADC的发现与临床前表征 JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications Benjamin Henley, Linxiao Chen, Megan Siani, Swetha Rao, Yi Fan, Kristen Wiley, Steve Pomerantz, Shalom Goldberg, Onyi Irrechukwu, Simone Buraschi, Suresh Kumar Swaminathan, Krista Burke, Tammy Bush, Bethany Mattson, Heather Deutsch, Gerald Chu, Jacalyn Clawson, Wan Cheung Cheung, Joshua M. Bauml, Ulrike Philippar, Smruthi Vijayaraghavan
-
- LB476 LB476 联合抑制转录起始与组蛋白去乙酰化触发血液肿瘤细胞死亡 Combined inhibition of transcription initiation and histone deacetylation triggers blood cancer cell death Jennifer Rose Devlin, Shenali Ranasinghe, Ben Martin, Nenad Bartonicek, Kaylene J. Simpson, Ricky W. Johnstone
-
-
